HomeInsightsDividend

RPG Life Sciences Ltd dividend

RPG Life Sciences Ltd dividend

download
stocks purchased

₹ 0.7 Cr

Volume transacted

stocks purchased

3.7 K

stocks traded

Last Updated time: 20 Jul 9.00 AM

Image

RPG Life Sciences Ltd

NSE: RPGLIFE

DPS

16

Last updated : FY 2024

Key Highlights

    The Dividend per Share of RPG Life Sciences Ltd is ₹ 16 as of 2024 .a1#The Dividend Payout of RPG Life Sciences Ltd changed from 39.73 % on March 2019 to 30.18 % on March 2024 . This represents a CAGR of -4.48% over 6 years. a1#The Latest Trading Price of RPG Life Sciences Ltd is ₹ 1791 as of 19 Jul 15:30 .a1#The Market Cap of RPG Life Sciences Ltd changed from ₹ 409.75 crore on March 2019 to ₹ 2530 crore on March 2024 . This represents a CAGR of 35.45% over 6 years. a1#The Revenue of RPG Life Sciences Ltd changed from ₹ 130.15 crore to ₹ 167.79 crore over 9 quarters. This represents a CAGR of 11.95% a1#The EBITDA of RPG Life Sciences Ltd changed from ₹ 29.06 crore to ₹ 41.44 crore over 9 quarters. This represents a CAGR of 17.08% a1#The Net Pr of RPG Life Sciences Ltd changed from ₹ 18.21 crore to ₹ 26.76 crore over 9 quarters. This represents a CAGR of 18.66% a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

Share Price Vs Dividend Yield

swot
swot

Company Fundamentals For RPG Life Sciences Ltd

Market Cap

2,962 Cr

EPS

52.5

P/E Ratio (TTM) *

34.1

P/B Ratio (TTM) *

7.9

DTE *

0.0

ROE *

23.4

ROCE *

31.3

Dividend Yield *

1.05

DPS *

16

Dividend Payout *

30.18

Ann.Dividend % *

200

* All values are consolidated

Last Updated time: 20 Jul 9.00 AM

* All values are consolidated

Last Updated time: 20 Jul 9.00 AM

×

Historical Dividend Payout of RPG Life Sciences Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of RPG Life Sciences Ltd

Period
Mar '1940
Mar '2025
Mar '2130
Mar '2231
Mar '2329
Mar '2430

* All values are a in %

Dividend per Share (DPS) Over Time

×

DIVIDENDYIELD

Dividend Yield is a financial ratio that shows the annual dividend income relative to the market price of a share. It is calculated by dividing the dividend per share by the current market price per share, expressed as a percentage.

Dividend Yield Comparison With Top Peers

1M

1Y

3Y

5Y

* All values are in %

Net Profit Vs Dividend Per Share

Image

RPG Life Sciences Ltd

NSE: RPGLIFE

PRICE

1791.4

-17.25 (-0.95%)

stock direction

Last updated : 19 Jul 15:30

SWOT Analysis Of RPG Life Sciences Ltd

Strength

2

S

Weakness

0

W

Opportunity

0

O

Threats

1

T

Overview of Dividend

Types of Dividend


Special Dividend

A dividend is paid on common stock when a company has accumulated substantial profits over years, often seen as excess cash that doesn't need immediate use.


Preferred Dividend

A quarterly dividend is paid to preferred stock owners, typically accumulating a fixed amount, and is earned on shares that function more like bonds.


Interim Dividend

Companies declare interim dividends before final full-year accounts are prepared, specifically in India, during the financial year from April to March of the following year.


Final Dividend

A final dividend is issued after the year's accounts have been compiled. Aside from this, the following list highlights the most prevalent sorts of dividends:


×

Historical Market Cap of RPG Life Sciences Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of RPG Life Sciences Ltd

Period
Mar '19410
Mar '20282
Mar '21640
Mar '22926
Mar '231151
Mar '242531

* All values are a in crore

×

Historical Revenue of RPG Life Sciences Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of RPG Life Sciences Ltd

Period
Jun '22130
Sep '22136
Dec '22131
Mar '23120
Jun '23150
Sep '23155
Dec '23156
Mar '24129
Jun '24168

* All values are a in crore

×

Historical EBITDA of RPG Life Sciences Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of RPG Life Sciences Ltd

Period
Jun '2229
Sep '2231
Dec '2230
Mar '2318
Jun '2334
Sep '2339
Dec '2340
Mar '2422
Jun '2441

* All values are a in crore

×

Historical Net Profit of RPG Life Sciences Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of RPG Life Sciences Ltd

Period
Jun '2218
Sep '2220
Dec '2219
Mar '2310
Jun '2322
Sep '2326
Dec '2326
Mar '2413
Jun '2427

* All values are a in crore

About RPG Life Sciences Ltd

About RPG Life Sciences Ltd

    RPG Life Sciences, formerly Searle India Ltd, started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to RPG Group. The Company is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The company is having research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. They are having TGA (Aus) and MHRA (UK) approved facilities at Thane in Maharashtra and Ankleshwar in Gujarat. RPG Life Sciences Ltd was incorporated on March 29, 2007 with the name RPG Pharmaceuticals Ltd. During the year 2007-08, as per the scheme of arrangement, the company acquired the pharmaceuticals business of Brabourne Enterprises Ltd along with all assets and liabilities pertaining to that business with effect from April 2, 2007 (the appointed date). In February 13, 2008, the name of the company was subsequently changed to RPG Life Sciences Ltd. During the year 2008-09, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes. They launched an oncology drug namely Exemestane. Also, they launched new products, namely Nufex Beta, Qugyl-O & Immunotec. In June 10, 2008, the equity shares of the company were listed on BSE and NSE with effect from June 10, 2008. In July 2008, the company commenced production in the new high capacity fermenters. During the year 2009-10, the company strengthened their product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. The new products launched during the year were Demator, Sizomax, Mela, Exinia and Mofetyl S. They launched a new immunosuppressant product, Sirolimus, during the year. Also, they introduced 11 new products across several therapeutic segments. The company plans to launch six new bulk drugs and two existing products in new markets. They also plan to file DMFs for several products in regulated and semi regulated markets. The company is having plans to set up dedicated divisions with their own sales force and portfolio of brands that will drive the business in therapeutic areas like oncology, psychiatry and diabetology. New products launched were Demator, Sizomax, Mela, Exinia and Mofetyl S during the year 2009-10. The Company strengthened its product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. It launched a new immunosuppressant product, Sirolimus in 2010. New divisions were launched in highly growing chronic segments namely Cardiology and Diabetic (IMPULSE), NeurologyPsychiatry (EMPATHY) and Oncology (Neo-life). A new division ESSENTIA was also launched to cater to the Hospital sales segment in 2010-11. New products launched were Seretane 2 DT, Rabee 20, Pedimec, Minilactone, Alfalog, Demator, Naprosyn Gel, Lamotrigine dispersible tablets. The Company sold its Biotech Unit located at Ankleshwar to M/s. Intas Pharmaceuticals Limited as a going concern in 2016-17. It acquired 7 brands from Sun Pharmaceuticals Limited, set up two new divisions viz. Urolife' catering to the urology therapy and Glodiance division catering to the Cosmetic Derma therapy in 2016-17. In 2017-18, the Company launched brands Darbepoetin (Darba) and Rituximab (XMAB), in the post-transplant care space. Both the brands displayed robust performances in the first year of launch with Darba at third slot among competing Darbepoetin brands. Among the existing products, Immunotac and Arpimune range showed strong growth. In the Africa region, the Company expanded its business with first commercial supply in FY'18. It retained leadership position in Mauritius, through anti-diabetic range while in Egypt, immunosuppressant range remained the best alternative to the innovator brands in the post organ transplant care space. During 2019, the Company focused on launching new products and driving active promotion in the immunosuppressant range of products and strengthened the oncology portfolio basket by introducing two new monoclonal antibodies. It launched a new product, T-JAKi (JAK Inhibitor) in the immunosuppressant range of products in Rheumatology and Gastroenterology in FY21. As a part of Life Cycle Management strategy of legacy products, Romilast BL and Aldactone T new line extensions were launched. Azoran 75 mg new line extension was launched in 2021. Naprosyn+ and Aldactone-F was launched in FY'22.

RPG Life Sciences Ltd News Hub

News

RPG Life Sciences to announce Quarterly Result

RPG Life Sciences will hold a meeting of the Board of Directors of the Company on 19 July ...

Read more

13 Jul 202410:33

News

RPG Life Sciences to convene AGM

RPG Life Sciences announced that the Annual General Meeting (AGM) of the company will be h...

Read more

12 Jun 202413:44

News

Board of RPG Life Sciences recommends final dividend

RPG Life Sciences announced that the Board of Directors of the Company at its meeting held...

Read more

02 May 202411:08

News

RPG Life Sciences to hold board meeting

RPG Life Sciences will hold a meeting of the Board of Directors of the Company on 30 April...

Read more

24 Apr 202410:29

News

RPG Life edges higher after ICRA upgrades LT rating to 'A+'

The credit rating agency has reaffirmed the company’s short-term rating at ‘ICRA] A1’. ICR...

Read more

06 Mar 202412:54

News

RPG Life Sciences to hold board meeting

RPG Life Sciences will hold a meeting of the Board of Directors of the Company on 1 Februa...

Read more

27 Jan 202414:29

FAQs for dividends of RPG Life Sciences Ltd

What is the current market price of RPG Life Sciences Ltd Ltd as of July 20, 2024?

The current market price of RPG Life Sciences Ltd Ltd stands at 1791.4 per share.

What dividend did RPG Life Sciences Ltd declare in the last fiscal year?

In the last fiscal year, RPG Life Sciences Ltd declared a dividend totaling ₹16.0.

What is the most recent dividend declared by RPG Life Sciences Ltd?

RPG Life Sciences Ltd recently declared a dividend of 0.0 in the latest quarter

How many times has RPG Life Sciences Ltd declared dividends in the current fiscal year

RPG Life Sciences Ltd has declared dividends 5 times totaling ₹0 in the current fiscal year (FY2023-2024).

How many times did RPG Life Sciences Ltd declare dividends in the previous fiscal year?

In the previous fiscal year (FY2022-2023), RPG Life Sciences Ltd declared dividends 4 times totaling ₹0.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199